No business leader is as qualified academically as Jim Tananbaum. Jim boasts of an undergraduate in math and engineering from the renowned Yale College. Tananbaum holds an M.S. from M.I.T., an M.D. from the prestigious Harvard Medical College and a postgraduate M.B.A. from the business school of Harvard. He has held advisory positions on the boards of Harvard, MIT, and Yale.
In the business world, Jim has achieved a lot. He stands as the founder of Foresite Capital, a company that is redefining entrepreneurship in the sector of bio-pharmaceuticals. Jim has built Foresite Capital to the successful venture it is by creating partnerships and franchises with market leaders and innovators in the industry of healthcare. His business model involves strategic investment and management of enterprises that are focused on coming up with modern and efficient therapies.
Before the birth of Foresite Capital, Jim Tananbaum had already made milestones in the sector of bio-pharmaceuticals. His creation, Prospect Venture Partners II and III and Sierra Ventures came up with two drugs on a modest budget of $80 million. Other investments that Jim has led include Amira Pharmaceuticals, Jazz Pharmaceuticals, Healtheon, and Amerigroup.
Foresite Capital is a different investment ship. The company marries some of Jim’s most important discoveries and experiences to create an enterprise that is people-centered. Foresite Capital is also keen on the use of technology to advance futuristic medical therapies. Jim is positive that genomic sequencing will become an everyday medical practice in the future. Genomic sequencing will enable medical experts to design more targeting and individual specific treatments.
Jim Tananbaum is listed as one of the most influential business leaders by Forbes. One of the most notable success stories of Jim’s career in bio-pharmaceuticals is Intarcia. Intarcia is a bi-annual medical implant for individuals who are living with diabetes type II. The therapy enables them to manage their sugar levels and shed some weight. This product is expected to be available in the market by the end of the year 2017. Millions of people living with diabetes are supposed to get relief by using the therapy.